Comparison of the duo of insulin-like growth factor binding protein-1/alpha fetoprotein (Amnioquick duo+<sup>®</sup>) and traditional clinical assessment for diagnosing premature rupture of fetal membranes

J of Obstet and Gynaecol

Ezugwu

Eke

et al. 2017

Self Cite

“…Here, we report the results of the Amnioquick duo+ versus PAMG‐1 test. Results of the cohort evaluated with Amnioquick duo+ versus conventional methods have been published separately …”

Section: Introductionmentioning

confidence: 99%

Accuracy and response time of dual biomarker model of insulin‐like growth factor binding protein‐1/ alpha fetoprotein (Amnioquick duo+) in comparison to placental alpha‐microglobulin‐1 test in diagnosis of premature rupture of membranes

J of Obstet and Gynaecol

Ezugwu

Eke

et al. 2017

Self Cite

“…The present study predicted histologically confirmed chorioamnionitis using the Chorioquick test, which was in line with criteria used in previous studies. 4,17,21 Compared to binary tests used in previous studies, the scientific evidence to assume that the semi-quantitative IL-6 marker in Chorioquick would be a good test to diagnose sub-clinical In conclusion, the present study-the first into the Chorioquick test-showed favorable utility for detecting chorioamnionitis in PROM and could be a more reliable, non-invasive rapid tool in a realworld clinical setting, especially for those with some degree of acute chorioamnionitis. To our knowledge, this was the first time that a semi-quantitative bedside test has been used to evaluate IL-6 from cervicovaginal secretions in women with PROM.…”

Section: Discussionmentioning

confidence: 71%

Diagnostic value of Chorioquick for detecting chorioamnionitis in women with premature rupture of membranes

Intl J Gynecology & Obste

Ukah

Onyiaorah

et al. 2020

Objective To determine the accuracy of a semi‐quantitative interleukin‐6 (IL‐6) vaginal secretion rapid test (Chorioquick) for detecting chorioamnionitis in women with premature rupture of membranes (PROM). Methods A prospective cohort study in five tertiary hospitals in Nigeria involved women with confirmed PROM at term and preterm PROM with or without suspected chorioamnionitis from August 1, 2017, to October 31, 2018. Cervicovaginal fluid samples were tested for chorioamnionitis using the Chorioquick test. Samples were repeated at decision to deliver. The test was considered positive if at least the indicator ‘IL‐6 low’ of the three Chorioquick biomarkers (low, medium, high) was positive, or negative if none of the biomarkers were positive. Chorioamnionitis was histologically confirmed post‐delivery using three tissue samples. Primary outcome measures were sensitivity, specificity, and accuracy. Results Of 73 women, on histological confirmation, 39 were true positive and 29 were true negative (for chorioamnionitis) to the Chorioquick test at repeat assessment. Overall, the Chorioquick test had a sensitivity of 97.5% (95% confidence interval [CI] 85.3–99.9), specificity 87.9% (70.9–96.0), and accuracy 93.2% (79.5–99.1). Sub‐group analysis of women <37 weeks of pregnancy showed a sensitivity of 100.0% (95% CI 83.4–100.0), specificity of 91.3% (70.5–98.5), and accuracy of 95.8% (82.5–99.5). Triple positive samples were 100.0% specific in all gestations. Conclusion Chorioquick showed favorable utility for detecting chorioamnionitis in PROM and could be a reliable, non‐invasive rapid tool in a real‐world clinical setting.

“…The AmnioQuick Duo+ test detects the presence of AFP and IGFBP‐1 in vaginal samples . The vaginal specimen was obtained via a swab stick placed in the posterior fornix for 1 minute.…”

Section: Methodsmentioning

confidence: 99%

“…The AmnioQuick Duo+ test detects the presence of AFP and IGFBP-1 in vaginal samples. 10 The vaginal specimen was obtained via a swab stick placed in the posterior fornix for 1 minute. A buffer tube was used to rinse the swab for 10 seconds; in some cases, the tip of the swab was broken off into the buffer tube and the contents were shaken.…”

Section: Methodsmentioning

confidence: 99%

Performance indices of AmnioQuick Duo+ versus placental α‐microglobulin‐1 tests for women with prolonged premature rupture of membranes

Intl J Gynecology & Obste

Ezugwu

Ezebialu

et al. 2018

Objective To compare AmnioQuick Duo+ versus the placental α‐microglobulin‐1 (PAMG‐1) test for diagnosis of prolonged premature rupture of membranes (PROM). Methods A multicenter prospective cohort study included women with suspected PROM at six tertiary institutions in southern Nigeria between January 1 and December 31, 2015. The inclusion criteria were features of PROM lasting at least 24 hours and a pregnancy duration of more than 24 weeks. AmnioQuick Duo+ (Biosynex, Strasbourg, France) and PAMG‐1 (AmniSure International, Boston, USA) tests were used to diagnose PROM, which was confirmed after delivery by any two of the following criteria: delivery within 48 hours to 7 days, chorioamnionitis, membranes perceptibly ruptured at delivery, and adverse perinatal outcomes considerably associated with prolonged PROM. Results Of 100 women assessed for eligibility, 99 were included. Sensitivity, specificity, and accuracy were, respectively, 97.3%, 100%, and 95.9% for AmnioQuick Duo+, and 93.2%, 100%, and 90.4% for PAMG‐1. The differences were not significant and the diagnostic discordant rate between the two tests was 3.1%. In equivocal cases (i.e., negative pooling test result), AmnioQuick Duo+ and PAMG‐1 performed equally (diagnostic accuracy, 100% vs 97.7%; P>0.99). Conclusion For diagnosis of PROM, AmnioQuick Duo+ was found to be non‐inferior and comparable in accuracy to the PAMG‐1 test, with a diagnostic discordance rate of 3.1%.